OncoMatch/Clinical Trials/NCT05790213
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Is NCT05790213 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Androgen Deprivation Therapy (ADT) for prostate cancer.
Treatment: Androgen Deprivation Therapy (ADT) — The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage ≤ CLINICAL STAGE T2C (clinical)
Excluded: Stage III, NODAL, IV
Grade: GG2GG3 (Grade Group)
a. Favorable intermediate-risk PCa: i. ≤ clinical stage T2c, GG2, and PSA ≤ 10 ng/mL, and <50% positive biopsy cores with PCa b. Unfavorable intermediate-risk PCa: i. ≤ clinical stageT2c, GG2, and PSA 10-20 ng/mL, or ≥50% positive biopsy cores with PCa, or ii. ≤ clinical stage T2c, GG3, and PSA < 20 ng/mL
Performance status
ECOG OR KARNOFSKY 0–2
ECOG performance status ≤ 2 or Karnofsky Performance Status Scale Score ≥ 60%
Demographics
Prior therapy
Cannot have received: biologic
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: chemotherapy
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: hormone therapy
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: radiotherapy
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: surgery
Subject has had prior or current PCa therapies, such as biologic, chemotherapy, hormone therapy, radiotherapy or surgery for PCa.
Cannot have received: pelvic radiation
Exception: for a separate hematologic or visceral malignancy within 6-months of enrollment
Subjects may not have had undergone pelvic radiation, chemotherapy or immunotherapy treatment for a separate hematologic or visceral malignancy within 6-months of enrollment in the present study.
Cannot have received: chemotherapy
Exception: for a separate hematologic or visceral malignancy within 6-months of enrollment
Subjects may not have had undergone pelvic radiation, chemotherapy or immunotherapy treatment for a separate hematologic or visceral malignancy within 6-months of enrollment in the present study.
Cannot have received: immunotherapy
Exception: for a separate hematologic or visceral malignancy within 6-months of enrollment
Subjects may not have had undergone pelvic radiation, chemotherapy or immunotherapy treatment for a separate hematologic or visceral malignancy within 6-months of enrollment in the present study.
Lab requirements
Blood counts
Hemoglobin ≥ 10 g/dL; Leukocytes ≥ 3,000/mcL; Absolute neutrophil count ≥ 1,500/mcL; Platelets ≥ 100,000/mcL
Kidney function
Creatinine < 1.5 institutional ULN OR Calculated or measured creatinine clearance > 50 mL/min/1.73 m2; eGFR >30 mL/min using the MDRD formula; Serum potassium ≥3.5 mmol/L
Liver function
Total bilirubin ≤ 1.5 x institutional ULN; AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN; Serum albumin ≥3.0 g/dL
Subjects must have adequate organ and marrow function as defined below: Hemoglobin ≥ 10 g/dL Leukocytes ≥ 3,000/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN Creatinine < 1.5 institutional ULN OR Calculated or measured creatinine clearance > 50 mL/min/1.73 m2 eGFR >30 mL/min using the MDRD (modification of diet and renal disease) formula Serum albumin ≥3.0 g/dL Serum potassium ≥3.5 mmol/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UChicago Medicine Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05790213 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage ≤ CLINICAL STAGE T2C is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages